Fluticasone propionate — Intranasal corticosteroid. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Fluticasone propionate
Class
Intranasal corticosteroid
Mechanism
A synthetic trifluorinated corticosteroid with anti-inflammatory activity and high glucocorticoid-receptor affinity in vitro. It affects inflammatory cells and mediators, but the precise mechanism of rhinitis symptom relief and the clinical significance of receptor-binding findings are unknown.
Used for
Nasal symptoms of perennial nonallergic rhinitis in adults and children aged 4 or older
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260805 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: A synthetic trifluorinated corticosteroid with anti-inflammatory activity. High glucocorticoid-receptor binding affinity is shown in vitro, but its clinical significance and the precise mechanism of rhinitis symptom relief are unknown.
On both cards: Used for — Nasal symptoms of perennial nonallergic rhinitis in adults and children aged 4 or older · Common side effects — Headache; Pharyngitis; Epistaxis; Nasal burning / irritation; Cough · Warnings — Epistaxis, nasal ulceration, septal perforation; Glaucoma and cataracts
Only on the Fluticasone card: Warnings — Hypercorticism and adrenal suppression · Interactions — Strong CYP3A4 inhibitors (e.g. ritonavir, ketoconazole)
Mechanism: Corticosteroid with potent anti-inflammatory effects on mast cells, eosinophils, and mediators; exact mechanism in rhinitis unknown.
On both cards: Common side effects — Headache; Pharyngitis; Epistaxis; Cough · Warnings — Glaucoma and cataracts
Only on the Mometasone Furoate (nasal) card: Used for — Prevention of seasonal allergic-rhinitis nasal symptoms in adults and children aged 12 or older; Chronic rhinosinusitis with nasal polyps in adults aged 18 or older · Common side effects — Viral infection · Warnings — Epistaxis, nasal ulcer, septal perforation; Adrenal suppression, slowed growth · Interactions — Strong CYP3A4 inhibitors (e.g., ketoconazole)
Mechanism: Binds with high affinity and selectivity to the CysLT1 receptor, inhibiting physiologic actions of leukotriene D4 in the airway.
On both cards: Common side effects — Headache; Pharyngitis; Cough
Only on the Montelukast card: Used for — Asthma prophylaxis and chronic treatment in patients aged 15 years and older; Prevention of exercise-induced bronchoconstriction in patients aged 15 years and older; Seasonal or perennial allergic rhinitis in patients aged 15 years and older only when alternative therapies are ineffective or not tolerated · Common side effects — Upper respiratory infection; Fever · Warnings — Not for acute asthma attacks; Systemic eosinophilia / Churg-Strauss; Aspirin sensitivity persists
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera